Edition #427 | December 2014
NOTE: FP Essentials #427 Hepatitis C cited treatment guidelines from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America in the text and in Table 3. These guidelines have been updated since publication. Please refer to the updated Recommendations for Testing, Managing, and Treating Hepatitis C(www.hcvguidelines.org).
FP Essentials is a monthly subscription containing authoritative, unbiased, and peer-reviewed clinical information -- without any advertisements.
Purchase this individual edition for online access to its content, and earn up to 5 CME credits upon completion of the quiz. Online access for this edition available until December 2016.
In This Edition
- Recommend appropriate screening for hepatitis C virus (HCV) infection based on current guidelines.
- Identify the primary ways in which HCV is transmitted.
- Use currently available noninvasive approaches for assessing the degree of hepatic fibrosis in patients with HCV infection.
- Describe three ways in which HCV infection management with the new direct-acting antiviral drugs differs from management with the older interferon-ribavirin combination.
- Determine a patient’s model for end-stage liver disease (MELD) score.
- Diagnose medical conditions that commonly develop in patients who have undergone liver transplantation.
- Diagnose the most common extrahepatic manifestation of HCV infection.
- Name three less common extrahepatic manifestations of HCV infection.
Approved for 5 AAFP Prescribed credits; 5 AMA PRA Category 1 Credits™. Credit valid through December 31, 2016.
Purchase This Edition
Online access only
#427: Hepatitis C
CME credit approved through December 31, 2016
Take the Quiz for CME Credit
Read It Online Now
Content accessible after purchase of this edition, FP Essentials Subscription, or FP Essentials + FP Audio Combined Subscription.